Carlos G Santos-Gallego, MD @SantosGallegoMD Twitter profile

Pinned Tweet

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

1

29

107

Last Seen Profiles

@bnyamin05619541

@osushivip

@colombian_TIE

@SpacetoonAghani

@Notyatyi

@SandraPhil49707

@NIGGADOREAN

@colombian_TIE

@erdemcan1759297

@IdellTap

@bokeplokalmalam

@LittleCasey_

@y_tamx

@osushivip

@phantasmm___

@YaleHousestaff

@FrankOrr255596

@daitainitoukin

@stw_pdg

@restore_lab

@signoresalieri

@JA6I2A_amapi

@BdallhAl77960

@Karanfilciim

@PatsLadi99

@otero23mary

@binch3229

@ingematland

@LoL_MatteoITA

@zerowrites

@papmantan69_

@alishriiii

@yuan88686069370

@irina_tomsk

@stw_pdg

@howardlee_my

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

A drug is finally able to improve outcomes in HFpEF! 🎉🎉 EMPEROR-Preserved phase III trial met its primary endpoint!!!! Empagliflozin demonstrated significant risk reduction for the composite of CV death or hospitalization for heart failure in adults with HFpEF

11

206

855

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Breaking news: FDA has just approved sotagliflozin (brand name "Inpefa") for Treatment of Heart Failure!!!! Broad label across full LVEF range (HFpEF&HFrEF), and for patients with or without T2DM First dual SGLT1/2 inhibitor to be approved in HF @DLBHATTMD @ChristosArgyrop

12

257

678

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

“Do SGLT2i also improve arrhythmias?” A real honor to be invited to discuss this topic at #HRS23 …even though I am not EP! #HRS2023 A great pleasure to present data of our collaboration with my great friends @jskoruth @iwanari65284818 #ConorOates @DLBHATTMD @ChristosArgyrop

11

66

203

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Boom! EMPA-KIDNEY stopped early due to clear efficacy as per Data Monitoring Committee 6609 patients, mean age 64, mean eGFR 37, uACR 412. Inclusion criteria eGFR 20-45 or 45-90 if uACR>200 Primary endpoint: CV-renal death, dialysis-renal transplant, sustained eGFR decline>40%

8

51

181

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

A drug is finally able to improve outcomes in HFpEF! 🎉 EMPEROR-Preserved phase III trial met its primary endpoint!!!! Empagliflozin demonstrated significant risk reduction for the composite of CV death or hospitalization for heart failure in adults with HFpEF

4

51

174

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Wow! Big news for HFpEF! Shall sacubitril/valsartan and spironolactone be FDA-approved for HFpEF? FDA Advisory Panel has just voted today 12-1 to approve an expanded indication for sacubitril/valsartan based on PARAGON-HF trial (with a tantalizing RR=0.87 [0.75-1.01], p=0.06)

10

33

165

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Great tweetorial about hemodynamics of pericardial disease. Do you still have doubts in constriction vs restriction? Do not miss this tweetorial by @mortkern

2

50

167

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

The world has lost a giant: Dr Bernard Lown - creator of the modern direct current defibrillator - creator of the coronary care unit - introducer of lidocaine for arrhythmia treatment - discoverer of the importance of potassium in digitalis toxicity - Nobel Peace Prize Laureate👇

2

57

151

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

An example of how dramatically Medicine has advanced. How to rescue a man from the snakebite of a cobra in 1928? "chickens, one after the other, with their anuses well stretched were applied to the site of the bite". You may need up to 96 chicken per patient!

12

57

149

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Proud to present tomorrow the latest evidence at #ADA2023 about SGLT2i and heart failure. Best panel ever with my friends Darren McGuire (discussing SGLT2i/GLP1RA) and @PamTaubMD (discussing GLP-1RA in CVD), moderated by @gandaom @DLBHATTMD @GoggleDocs

5

40

144

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

Very proud to be invited to lecture at #AHA2023 about dual SGLT1/2 inhibition as a novel strategy for HFpEF! Saturday 11/11 at 3.15-4.30pm to learn HFpEF therapies from amazing experts @mvaduganathan @andrewjsauer @FudimMarat @HFpEF @KMAlexanderMD @JenHoCardiology @RBPatelMD

12

19

139

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Bayer’s Finerenone Meets Primary Endpoint (4 point MACE of CV death+MI+stroke+HF hospitalization) in Phase III FIGARO-DKD In T2DM+CKD patients, finerenone improves renal endpoints (FIDELIO trial) and now also improves CV endpoints (FIGARO) @ChristosArgyrop @AndrewJSauer

3

65

131

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

In CKD patients, SGLT2i are estimated to prevent dialysis by 15 years! #GlobalTrialsSummit If we assume same loss of eGFR in the future as during CANVAS, placebo arm would reach threshold for dialysis n 10 years, the SGLT2i arm would reach it in 25 years! @ChristosArgyrop

4

40

105

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸 That is 8% of the going price of empagliflozin or dapagliflozin!! Caveat: Only indication in T2DM (not HF or CKD) @ChristosArgyrop @JonathanDavisHF @AndrewJSauer @hvanspall @dranulala

TheracosBio teams with Mark Cuban's Cost Plus to launch Brenzavvy at bargain price

As another SGLT2 diabetes drug hits the market, the obvious question is: How will it find a way to compete against formidable blockbusters Farxiga and Jardiance? | TheracosBio and Mark Cuban's online...

www.fiercepharma.com

9

23

105

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

When Braunwald quotes your EMPATROPISM study at his AHA presentation 😎 This made my day! @RequenaIbanez @juanbadimon @Jcontreras75 @dranulala @spinneymd @DonnaMancini11 @samtori

8

11

102

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

It was an outstanding honor to be invited to lecture at #ADA2022 about SGLT2i in HFpEF! Loved the session, the lively discussion, all the amazing science presented in other sessions, how exquisitely the meeting was organized! It was my first ADA, and -for sure- the first of many!

10

3

96

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

After two years of online friendship, it has been amazing and heartwarming to finally meet @JJheart_doc in person! To talk about his life and professional trajectory, ARNI, SGLT2i, medical therapy (in HF and atherosclerosis), important stuff such as soccer,…

5

7

92

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

So proud to have lectured today at #ESCCongress about SGLT2i! Thanks for the invitation, @escardio ! Session: Meet the Experts: fuel up! – targeting cardiac energy metabolism in type 2 diabetes and HF… Title: ... By Pharmacological Interventions: SGLT2i in heart failure

11

20

86

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

🤣🤣So true! @ChristosArgyrop @Sglt2inhibitorL @JJheart_doc @ShelleyZieroth @hvanspall @j_alvarezgarcia @m_rivaslasarte @Borjaibanez1 @DrRajivsankar @rachkataria @HanCardiomd @KevinShahMD @paomorejon @lucreciamburgos @AHajduczok @AlexNowbar @DrNasrien @scoca1 Via @ezmanshariff

2

23

82

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Dapagliflozin approved in the US for the treatment of CKD in patients at risk of progression independently of T2DM #DAPACKD Dapagliflozin becomes 1st #SGLT2i in class to be triple indicated ( #T2D #HF #CKD ) Also approved for eGFR downt to 25

3

27

76

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Our manuscript about the EMPATROPISM trial accepted in @JACCJournals as simultaneous publication with our presentation at #AHA20 as Featured Clinical Trial! What an honor! Effect of empagliflozin on LV volumes, LV mass, LVEF&peakVO2 in non-diabetic HFrEF patients #whyCMR #CPET

12

9

74

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

FDA finally approves inclisiran. Only two doses per year of a PCSK9 inhibitor to reduce LDL-C!

TCTMD

@TCTMD

3 years

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

4

68

218

2

21

74

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Love this subanalysis of PROVE-HF by @JJheart_doc Sacubitril/valsartan ⬆️ANP and its biological activity (⬆️cGMP) The larger the ⬆️ in ANP, the more reverse remodeling Because it is an inert fragment, NT-proBNP is only a marker of HF, not a mediator➡️S/V may act via ANP

1

29

70

Carlos G Santos-Gallego, MD

@SantosGallegoMD

6 months

What a masterful tour-de-force lecture about “Genetics in Cardiology” by @pnatarajanmd as a Visiting Professor at @MountSinaiHeart ! He mesmerized the audience with the breadth and the depth of his knowledge! @DLBHATTMD @dranulala @Drroxmehran @Jcontreras75 @GeneticHeartDoc

3

7

69

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

So pleased to meet in person with @hvanspall and @JJheart_doc at #ADA2022 ! They are two giants of Cardiology, but most importantly two amazing human beings. Thanks for your friendship, company, generosity, conversation, and mentorship!

6

2

68

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Very proud to see our EMPATROPISM trial in the top 10 of 2021 JACC’s MOST IMPACTFUL PAPERS IN SOCIAL MEDIA! Congrats to the amazing team that achieved this feat @RequenaIbanez @Jcontreras75 @dranulala @DonnaMancini11 @spinneymd @juanbadimon Read the paper

JACC Journals

@JACCJournals

3 years

The 2021 Most Talked About list of #JACCJournals articles are now live! See the articles that received the most online media and social media attention 🌎 this year ➡️ #CardioTwitter

0

7

26

10

14

67

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

SGLT2i, useful even in cats! FDA approves bexagluflozin for T2DM in cats 👇 @ChristosArgyrop @AnastasiaSMihai @hvanspall @mvaduganathan @AndrewJSauer @gcfmd @JJheart_doc @hswapnil @acorderofort @ValleAlfonso @SeguraCardio @rachkataria @JonathanDavisHF @AHajduczok @RyanTedfordMD

Daniel J Drucker

@DanielJDrucker

2 years

Bexagliflozin, marketed as Bexacat, developed by Theracos, is the first @US_FDA approved once daily SGLT-2 inhibitor for cats with #diabetes

7

19

78

8

19

67

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Congrats @m_rivaslasarte for this important article about the dynamic correlation between cardiac filling pressures and B-lines by LUS ! You are the LUS Jedi Master!

6

23

65

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

What a week for CV Pharmacology! FDA approves the non-steroidal MRA finerenone for treatment of CKD associated with T2DM!! Great results in Fidelio and Figaro RCT! @ChristosArgyrop @kidney_boy @md_pollack @cardiomet_CE @rachkataria @DrRajivsankar @jlgorriz @GeorgeVasquezR2

Bayer | Pharmaceuticals

@BayerPharma

3 years

#News : Bayer announces U.S. #FDA approval of investigational therapy for the treatment of #chronickidneydisease associated with #type2diabetes :

1

39

87

2

27

65

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

SGLT2i are not associated with an increased risk of non-traumatic fractures in older people when compared with DPP-4i or GLP-1RA More great news about the safety of #flozins @radcliffeCARDIO @cardiomet_CE @ChristosArgyrop @Nephro_Sparks @ckd_ce @scoca1

1

20

62

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

So happy to finally meet in person @lucreciamburgos after two years of online friendship (since SoMe for #CVCT20 , 🥐commando). Enjoyed a lot your visit to @MountSinaiHeart ! @drdargaray

9

4

62

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

What a brilliant conference about heart failure leadership! Such useful messages! @robmentz @AndrewJSauer @dranulala

5

22

63

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

To be cost-effective, SGLT2i should be 17% cheaper, insulin glargine 30% cheaper, and GLP-1 mimetics 98% cheaper 😱

2

8

61

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

My experience with SGLT2i? Very effective and incredibly safe!!! @Sglt2inhibitorL @ChristosArgyrop @gmsamaras @AnastasiaSMihai @hvanspall @JJheart_doc @FudimMarat @mvaduganathan @scoca1 @kirkcampbell @dranulala @j_alvarezgarcia @acorderofort @gcfmd @ValleAlfonso @JTLLERGO

Dr. Lady Maria

@DrLadyMaria

3 years

Carlos Garcia Santos-Gallego is here to talk about - Pharmacological interventions: #SGLT2i in diabetic #heartfailure @escardio what’s your experience? @PeroneFrancesco @SilCastelletti @DrMarthaGulati @AndreasGevaert @MarinaBersaoui @hansen_phd @biljana_parapid #ESCcongress

0

28

52

8

21

61

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

So honored to be able to offer my perspective about the benefits of SGLT2i in heart failure in this article by the great @michaelTCTMD and @TCTMD . An honor and a pleasure to work with you1 #GDMT #flozinator

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

HF hospitalizations were reduced in all patients, yet only the higher-risk diabetic patients gained the survival advantage.

www.tctmd.com

11

18

59

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

A 2nd-year med student published as single author the discovery of heparin today 106 years ago Isolated from canine liver (“hepar” or "ήπαρ"="liver" in Greek) @ChristosArgyrop @AndrewJSauer @gcfmd @CMichaelGibson @Drroxmehran @CardioNerds @MKIttlesonMD

Stephen

@SteveYangMD

2 years

On this day in 1916, Jay McLean, a 2nd-year medical student, publishes the report showing his discovery of heparin at Johns Hopkins Hospital. #CTSurgery

19

193

1K

1

16

59

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Amazing talk today by @JonathanDavisHF about implementation of GDMT! Very interesting the part re: barriers to care (amazing job he does in the addiction clinic) Loved his tips&tricks to implement flozins-ARNI-MRA-BB @AHajduczok @rachkataria @gcfmd @AndrewJSauer @JJheart_doc

4

20

58

Carlos G Santos-Gallego, MD

@SantosGallegoMD

6 months

A new hope! The FDA just approved sotatercept for PAH! Potentially revolutionary news for PAH as it is the first drug acting on a new mechanism (not being a vasodilator like PDE5i-ERA-prostanoids) My opinion here (thanks Madison Muller for contacting me)

3

9

58

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

So proud and honored to provide commentary for @TCTMD about the potential and promising benefits of flozins for HFpEF in this combined SOLOIST/SCORED analysis! @DLBHATTMD Kudos to @michaelTCTMD for the insightful article and the depth of his knowledge!

1

14

56

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

@VLSorrellImages @ASE360 @CASEfromASE The flow of the LVOT varies a lot beat to beat. This ma happen in cases of severe LV systolic dysfunction and very remodeled LV. "Equivalent" to pulsus alternans. Therefore, I will guess LVEF 20%

2

51

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

And just like that…renal denervation (ultrasound, Paradise/Recor) is FDA-approved A therapy in search of the adequate patients @AnastasiaSMihai @mvaduganathan @SJGreene_md @ChristosArgyrop @Nephro_Sparks @jbrianbyrd @brendonneuen @kidney_boy

9

20

55

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Wonderful to meet (some of) the @GoggleDocs @AmarPut @drpatrickholmes at #ADA2022 Great food, greater (and larger) portions, amazing conversation, lot of fun @hvanspall @drsarahjdavies @drkevinfernando , we missed you!

3

2

54

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

EMBRACE-HF study: empagliflozin reduced diastolic pulmonary artery pressure (using CardioMEMS) in patients with HF (reduced or preserved EF) with or without diabetes (p=0.02) The curves separated almost immediately @dranulala @j_alvarezgarcia @m_rivaslasarte @RequenaIbanez

5

15

51

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Dear everyone attending #ACC23 , to my friends & new friends I have yet to meet, do not miss this #CardioTwitter #TweetUp 📆 Sunday March 5 🕘Time: 9pm- whenever 🗺️ @ritzcarlton #nola Davenport Lounge 🍷🎷🎶🥁🥂 All Invited Please RT! Thanks @DrMarthaGulati for organizing it!

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

@DrMarthaGulati

2 years

I know it seems far away but #ACC23 is just around the corner! That means #CardioTwitter #TweetUp so mark your calendars 📆 Sunday March 5 🕘Time: 9pm- whenever 🗺️ @ritzcarlton #nola Davenport Lounge (same place as Pre-COVID 2019) 🍷🎷🎶🥁🥂 All Invited Please RT! @DBelardoMD

3

50

114

2

12

52

Carlos G Santos-Gallego, MD

@SantosGallegoMD

7 months

Top line FLOW results. RCT of Semaglutide in 3533 T2DM with CKD. Impressive 24% reduction in the composite outcome driven by both kidney and cardiovascular components contributing

4

9

50

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Thanks so much @DrMarthaGulati & @MGsHusband for your hospitality! The best part of this trip was seeing you again, and meeting #BinkleyLove & #CocoLoco The ginger shot was delicious and actually mild (re: @mmamas1973 ) The early hike was gorgeous (re: @AnnaKateBarton ) @hvanspall

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

@DrMarthaGulati

2 years

This is how the #gingershot is done! @SantosGallegoMD didn’t complain unlike some ( @mmamas1973 I am speaking to you!) @HeartOTXHeartMD @dranulala @vbluml @robmentz @AndrewJSauer @QuentinYoumans @AHajduczok

8

1

35

6

49

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 months

So thrilled to have the extraordinary and amazingly talented clinician @JeffTeuteberg as our Visiting Professorship at @MountSinaiHeart Leading the change for biomarkers to replace cardiac biopsy in cardiac transplant surveillance @DLBHATTMD @dranulala @spinneymd @DonnaMancini11

3

7

49

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

So proud that the word “flozinate” has permeated so much that it has even entered Urban Dictionary! Plus, I love the definition “use an SGLT2i punch renal disease in the face” 😎 “Flozinators of the world, unite” @ChristosArgyrop @gmsamaras @NephroGuy @kidney_boy @Nephro_Sparks

Kam Kalantar-Zadeh, MD, MPH, PhD

@kamkalantar

3 years

@Sglt2inhibitorL Urban Dictionary: flozinate I am concerned that our enthusiastic #flozinators colleagues may cause the same problem that the then "ACEi"ors did in early 90's by declaring that ACEi would end ERDS, so no more low protein diet, and here again 30 years later

1

4

6

1

13

48

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Thanks so much @paomorejon @MoniGilbertO @ClinicaGquil for the invitation to lecture about SGLT2i at the First Course in Critical Cardiology! #flozins mechanism and use in acute heart failure! Amazing lecturers and very in-depth discussions Next year in person in Ecuador!

5

14

47

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

@bmwiernik Unfortunately, I know many journals which artificially increased their impact factor by requesting authors to quote 4 articles from the last 2 years published in that same journal

2

43

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

@AndrewJSauer @adrianbye If Sue tells you she does not feel right about one patient, you run to see that patient

3

47

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

I have learnt so many concepts about RV evaluation from thr master himself, the one and only @RyanTedfordMD , in the Grand Rounds at #McMaster organized by @hvanspall Importance of RV/PA coupling over contractility, of exercise/pharmacological reserve over at-rest evaluation,…

Harriette Van Spall, MD MPH

@hvanspall

1 year

So many insights by THE @RyanTedfordMD at #McMaster #CardiologyGrandRounds Important differences between systemic & pulmonary #circulation ; relatively more distal/small vessels in pulmonary circ Important differences in RV & LV. #RV more sensitive to changes in #afterload

3

19

69

1

13

47

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Cardiologists represented ONLY 1.5% of SGLT2i prescriptions and 0.4% of GLP-1RA prescriptions in 2020!!!! This is changing (12‐fold increase in SGLT2i and 4‐fold for GLP‐1RA), but we have to do better @ChristosArgyrop @Nephro_Sparks @ShelleyWood2 @hswapnil @kidney_boy @NephroGuy

Alfonso Valle

@ValleAlfonso

2 years

🇺🇸 Trends in Use of SGLT2i & arGLP1 by Cardiologists and Other Specialties, 2015 to 2020 👉 Monthly prescriptions from cardiologists ⬆️x12 for SGLT2i ⬆️x4-for GLP-1RAs 👉cardiologists represented only 1.5% of SGLT2i prescriptions and 0.4% of GLP-1RA prescriptions in 2020

3

28

75

3

10

48

Carlos G Santos-Gallego, MD

@SantosGallegoMD

6 months

What a tour de force by the amazing @PamTaubMD as Visiting Professor at @MountSinaiHear ! She masterfully took us through her journey from cardiometabolism to time-restricted eating to POTS to Long Covid, all with impeccable scientific accumen and humility! @DLBHATTMD

Anu Lala-Trindade

@dranulala

6 months

Wow. Jaw droppingly great talk 🗣️delivered by the one & only @PamTaubMD on how mitochondrial fcn underlies cardiometabolic syndrome, POTS & long-COVID. 🫀Prevention & #FunctionNotFailure are inextricably linked!!! Humble brilliance at its finest 🙌🏽 @MountSinaiHeart @DLBHATTMD

0

7

44

2

5

44

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

@ValleAlfonso @DLBHATTMD @radcliffeCARDIO @secardiologia @Dr_Manito @SENefrologia @jlgorriz @mvaduganathan @paomorejon @AmbrizMau @rafavidalperez @JTLLERGO @hvanspall The most novel take away from the talk by @DLBHATTMD is the antidiabetic efficacy of SGLT1i is not lost at ⬇️eGFR, while conversely SGLT2i lose their glycosuric (but not natriuretic) effect at ⬇️eGFR This is likely due to inhibition of intestinal absorption of glucose via SGLT1i

2

13

43

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

“If you want to go fast, go alone If you want to go far, go with your team” This is the best team for heart function/failure in the world Such a great night celebrating the holiday party of our Heart Failure team @MountSinaiHeart 🎄🕎 Merry Christmas! חנוכה שמח Chag Urim Sameach!

0

6

42

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Proud and honored to be chosen to write this "Overview of aspirin and platelet biology" with my mentor @juanbadimon for this accredited supplement of the American Journal of Cardiology #cardioed #meded Read the full issue

Charles Pollack MD

@md_pollack

4 years

Check out this accredited supplement to the American Journal of Cardiology, now available at , on the diminishing role of ASA in CV medicine. #cardiotwitter #platelets @cpcannon @DLBHATTMD @TYWangMD @DFCapodanno @SantosGallegoMD @academiccme

0

1

6

3

15

43

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

GDMT for HF! NNT 9 for spironolactone to prevent 1 death @gcfmd @JJheart_doc @AndrewJSauer @AHajduczok @DrMarthaGulati @hvanspall

Ryan Caputo, PharmD, BCCP

@RyanCaputo1

2 years

NNT to prevent 1 death from any cause Aspirin for secondary prevention: 333 Spironolactone for HFrEF: 9 If discharging a CAD patient without aspirin sounds crazy, then what does that say about discharging a HFrEF patient without an MRA?

12

132

701

1

9

41

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Second dose of the vaccine against Covid-19!!!! So excited and happy! Vaccines are safe and effective, so please everybody get vaccinated when it is your turn!

2

1

41

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

@Sglt2inhibitorL @Nephro_Sparks @ChristosArgyrop @hswapnil @AnastasiaSMihai @HanCardiomd @kidney_boy @JeremySussman @thebyrdlab Billions spent on Vitamin D testing and supplementation each year Yet another large scale, well powered RCT shows No entry sign health gains The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality

6

9

36

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

@RyanTedfordMD @EiranGorodeski @FudimMarat @DukeHFDoc @gcfmd @rcstarling @docbhardwaj I tip my hat to this comment

1

0

39

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Very clinically relevant questions in decongestion What do you think? @JJheart_doc @AndrewJSauer @RyanTedfordMD @hvanspall @ShelleyZieroth @DrMarthaGulati @TomCascinoMD @ankeetbhatt @AlexMebazaa @kidney_boy @ChristosArgyrop @scoca1 @Nephro_Sparks @SJGreene_md @FudimMarat

Jeroen Dauw

@JeroenDauw

2 years

What would be your loop diuretic strategy in this patient with acute #heartfailure and volume overload ? 🔹decreased eGFR 37 mL/min (normally around 52) 🔹Na 135 K 3.6 🔹80 furosemide od at home Please explain your choice. #cardiotwitter Question 1/3: what initial dose?

9

12

39

4

16

37

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

MRA: that cheap, incredibly effective, sadly underutilized drug (only 33% in the CHAMP registry) that improves outcomes in HFrEF @AndrewJSauer @AHajduczok @AnastasiaSMihai @ChristosArgyrop @DrMarthaGulati

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA

3 years

Excellent retro data demonstrating increase in MRA use but not hospitalization for hyperK+. #gdmt #HF @hfsa @APAC_Cardiology Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospita... @DrNasrien @leyadiel

1

13

28

0

8

38

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

SGLT2i improve outcomes in heart failure, CKD, T2DM, probably in obesity and NASH It is not a question of lack of evidence anymore but of implementation Flozinate! @ChristosArgyrop @gmsamaras @NephroGuy @AHajduczok @gcfmd @mvaduganathan @md_pollack @Sglt2inhibitorL @HanCardiomd

cardio-met

@cardiomet_CE

3 years

#Flozinate !

0

2

7

0

5

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

So proud and honored to lecture tomorrow about SGLT2i at the Valencian Society of Cardiology, Spain @SVCardio The dream team of panelist @ValleAlfonso @rdelaespriella @rachel_vilella Moderated by @lualmenar @mi_cardiologo @yulnunezvill Free registration

SVCardio

@SVCardio

3 years

Sesión miércoles 28. 🕒18h Modera @lualmenar @mi_cardiologo @yulnunezvill 📌 Los nuevos mecanismos iSGLT2 con @SantosGallegoMD 📌Futuro iSGLT2. Nuevos estudios con @ValleAlfonso 📌iSGLT2 en el paciente congestivo. @rdelaespriella 📌iSGLT2 en ICrFEVI @Rachel_Vilella

1

13

27

2

16

38

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

A must read article! Outstanding thread by @FudimMarat about the concept of preload reserve in the pathophysiology and treatment of HFpEF @ChristosArgyrop @gcfmd @JJheart_doc @HanCardiomd @ValleAlfonso @SantasEnrique @kevin_damman @FH_Verbrugge @j_alvarezgarcia @m_rivaslasarte

Marat Fudim, MD MHS

@FudimMarat

4 years

1. "Heart" Failure is not only a problem of the heart. The ability to modulate preload (aka Preload Reserve) is central to activity/exercise. Find the review on ⚡️Extracardiac Abnormalities of Preload Reserve in HFpEF⚡️ @sobotka_paul MarkDunlap @CircHF

6

58

154

0

13

37

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

What a masterful tour de force by @mvaduganathan reviewing the different cardiometabolic drugs and their effects on heart failure!! @SumeetMitter @dranulala @NoahMossMD @PPirlamarla_MD @Jcontreras75 @RequenaIbanez @DonnaMancini11 @DLBHATTMD @MountSinaiHeart

Sumeet Singh Mitter, MD, MSc

@SumeetMitter

2 years

Incredible talk by the one and only @mvaduganathan - an international leader in cardiometabolic heart failure trials - @MountSinaiHeart this morning. Let’s keep pushing the field forward @ACCinTouch 🚫🍬💔 ➡️💗 @dranulala @PPirlamarla_MD @NoahMossMD @DLBHATTMD @JJheart_doc

0

2

17

1

11

38

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

@AHajduczok @drkaushikjain @purviparwani @pnatarajanmd @AndrewJSauer @RyanTedfordMD @rcstarling @DLBHATTMD @docbhardwaj @MunirJanmohamed @DrMarthaGulati @DBelardoMD @KevinShahMD @Ron_Witteles @AmitGoyalMD @HafizaKMD @MarkDrazner @kkjdotai The next frontier of SGLT2i is acute HF (nice image summarizing all RCT). Right now, we only have data for SOLOIST (more of a subacute initiation of SGLT2i on the day of discharge) and EMPA-RESPONSE @kevin_damman

1

16

36

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Empagliflozin reduced the risk of HF hospitalization by ≈30% in all LVEF subgroups, with an attenuated effect in patients with an ejection fraction ≥65% @ChristosArgyrop

Muthu Vaduganathan

@mvaduganathan

3 years

Published today in @escardio #EHJ by @JavedButler1 . Empagliflozin effects in HF across LVEF as a continuous function in #EMPEROR Spline for primary endpoint (CVd+ first HFH) appears convincing for benefits across the board without significant interaction

2

17

57

0

12

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Great news for Nephrology! A small molecule targeting APOL1⬇️proteinuria by 48% in a phase-2 proof-of-concept study (n=13) of patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS) @VertexPharma (huge CKD cause in African Americans) @askrenal @ChristosArgyrop

2

6

34

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Diagnosing infective endocarditis only with you eyes and ears. Great thread by the outstanding @AndreMansoor Actually, diagnosing just with your brain because "The ears can't hear what the mind doesn't know." #meded #cardioed #echofirst #whyCMR #yesCCT

André Martin Mansoor

@AndreMansoor

3 years

1/6 A young man is admitted to the hospital with malaise and fever. You examine his hands and find these tender nodules. This should generate a hypothesis. (Heart sounds in this thread best heard with headphones or a decent computer speaker)

28

553

2K

0

15

34

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

FDA has just approved tirzepatide for weight loss (with one concomitant weight-related condition) under name Zepbound We now have another tool to help our patients...but it is a multifaceted approach Also, the war GLP1-RA vs GLP1/GIP-RA has started

4

7

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

A true honor to start 2021 Thank you @robmentz @dranulala for the opportunity to serve @JCardFail as Editorial Board Member! It is a great honor to work with you! A pleasure to serve our #HF community well

0

2

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Amazing talk about GLP-1RA by the incredibly talented @PamTaubMD ! Loved that she focused on novel fields beyond the "traditional" weight loss effects #ADA2023

2

18

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Congrats @RequenaIbanez for your first-author publication demonstrating that empagliflozin improve patient-reported outcomes (PRO) in HFrEF in our EMPATROPISM trial! Hard work and great ideas always pay off!

Alfonso Valle

@ValleAlfonso

3 years

⚠️Empagliflozin improves quality of life in nondiabetic HFrEF patients Sub-analysis of the EMPATROPISM trial @secardiologia @IcyfaSemi @SantosGallegoMD 📂

1

23

64

1

12

33

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

SGLT2i improve quality of life in HFpEF. Evidence confirmed in Emperor-Preserved, Preserved-HF and the “fully virtual/remote” Chief-HF Also, the effect of SgLT2i is consistent in all QoL strata, is not modified by baseline QoL @ChristosArgyrop

Giuseppe Galati

@GiuseppeGalati_

3 years

👆 #CHIEF_HF #SGLT2i definitely improve #QoL especially of #HFpEF @SJGreene_md @JBauersachsMD @DBelardoMD @gbiondizoccai @SABOURETCardio @DocSavageTJU @HeartOTXHeartMD @lucreciamburgos @torresviera @gabianfortes @FormigaFrancesc @ValleAlfonso @radcliffeCARDIO @markcpetrie20

0

7

24

3

12

34

Carlos G Santos-Gallego, MD

@SantosGallegoMD

9 months

A real tour-de-force conference by the great @scottdsolomon as a Visiting Professor at @MountSinaiHeart today discussing HFpEF Very interesting the different HFpEF phenotypes according to geography! #ValentinFuster @DLBHATTMD @spinneymd @dranulala @DonnaMancini11 @DrNasrien

Anu Lala-Trindade

@dranulala

9 months

What a privilege 🙌🏽 to have @scottdsolomon visit with us at @MountSinaiHeart today! Sitting behind giants #ValentinFuster & @DLBHATTMD in awe of tremendous contributions made in the field of #FunctionNotFailure particularly among those with EF>40%

1

8

76

0

5

35

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

Biostatistics made easy. The truth about propensity score matching @ChristosArgyrop @gmsamaras @mikejohansenmd @JJheart_doc @RezaMohebiMD @hvanspall @AndrewJSauer @scoca1 @girish_nadkarni @almucastro01 @acorderofort @ShelleyWood2 @mvaduganathan @docbhardwaj @CVCTForum @samtori

Martin Halla

@HallaMartin

2 years

Yet another one of those illustrations why (propensity score) matching might not do the job #EconTwitter

68

711

5K

7

6

33

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Should SGLT2i be used prior to MitraClip? Medical treatment should be optimized before MitraClip as per COAPT trial, and SGLT2i induce reverse remodeling, so this group says YES! @JJheart_doc @hvanspall @j_alvarezgarcia @m_rivaslasarte @ValleAlfonso

Neal Dixit, MD

@NealDixit

4 years

We reference an important recent work by @SantosGallegoMD et al to support our conclusion. @JeffHsuMD @gcfmd @boback @datsunian @SrivastavaPrat

3

0

8

2

8

34

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

@VLSorrellImages @ASE360 B. False. 1) The aortic valve closes progressively (the shape is triangular instead of rectangular), 2) there is a mid systolic notch in the aortic valve displacement showing premature closure of aortic valves, 3) there is very reduced systolic excursion of aortic root

2

0

33

Carlos G Santos-Gallego, MD

@SantosGallegoMD

10 months

Team work is Dream work (Spanish) food in company of friends taste much better #ChristmasLunch #comidadenavidad

Marcos Ferrández Escarabajal

@ferresc92

10 months

Celebrando como en casa 🇺🇸🇪🇸 @CasaGaliciaNYC Felicidades!! @RequenaIbanez @SantosGallegoMD @juanbadimon

0

14

1

0

33

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

The Social Media Ambassadors for #CVCT2022 celebrating a very successful&enlightening day @rachkataria @docbhardwaj @DrRajivsankar @DrRaniKhatib @drdargaray @aayshacader @SolovevaAnzhela @AHajduczok @JonathanDavisHF @AlexMebazaa @FaiezZANNAD @hvanspall @ShelleyZieroth @CVCTForum

3

8

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Great summary of benefits of SGLT2i Also SGLT2i reduce the risk of AKI!!!! There are also promising new therapies: MRA (finerenone, FIDELIO) and endothelin inhibitors (atrasentan, SONAR trial) @jardine_meg @ChristosArgyrop

1

14

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

The Paradise Ultrasound Renal Denervation System (ReCor Medical) received a positive review from an FDA advisory panel today (voted 10-2 that benefits outweight risks). The panel will reconvene tomorrow to evaluate radiofrequency renal denervation (Symplicity Spyral, Medtronic)

0

11

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

10 months

Fully agree! Shout out to Irina Rojnova, who both keeps the show running and is also an amazing and kind human being #CVCT2023 @CVCTForum @FaiezZANNAD #bosslady

Harriette Van Spall, MD MPH

@hvanspall

10 months

#IrinaRojnova , who keeps things moving @CVCTForum #BossWoman #CVCT2023

2

3

69

5

3

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

1/n Positive results for EMPEROR-REDUCED: Empagliflozin improves outcomes in HFrEF independently of diabetic status @scoca1 @girish_nadkarni @RequenaIbanez @BPicatoste @LoArLeCC @dranulala @EstefaniaOS @j_alvarezgarcia @m_rivaslasarte @aishaikh

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regardi...

www.nejm.org

2

16

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Excellent animation about the EKG changes of hyperkalemia!

Sam Ghali, M.D.

@EM_RESUS

4 years

Here’s your AMAZING reminder of the classic #ECG changes of ↑K+ Your ability to recognize these will save lives! #FOAMed

38

2K

6K

0

6

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

Great to finally meet in person @pabeda1 ! #AHA2023

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦

@pabeda1

11 months

Glad to catch up with @SantosGallegoMD at #AHA23 ! #CardioTwitter #cardioEd

3

1

31

2

0

32

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

So proud that our EMPATROPISM trial has been mentioned in @CardioNerds @CardioNerdsJC #cardsJC , the favorite learning method of all Cardiology Fellows! @RequenaIbanez @dranulala @Jcontreras75 @juanbadimon @DonnaMancini11 @spinneymd @SinaiCards @MountSinaiHeart @MSMCardsFellows

CardioNerds Journal Club

@CardioNerdsJC

3 years

Contrast this with HFrEF, for which numerous life-prolonging ⌛️ strategies are available. Check out an overview of these treatments for HFrEF by @CardioNerds fellow @TDonisan #HouseTaussig #CardsJC

2

19

62

0

11

31

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

Hear hear👇🏻 The faces that will change clinical trials by increasing diversity Thanks to the charismatic @DrRobWinn and @WinnAwards (I am also adding some more photos of cardiology-Cohort 2 & of all cohorts together) @Kfarooqi @DrLaPrincess @eberly_lauren @DrKarenOrjuela

Dr. Kanwal M Farooqi

@Kfarooqi

11 months

Remember these faces! They will be changing the clinical trials landscape!!! Thank you to the @WinnAwards and @DrRobWinn for the support, education and guidance these last two years. We 🫶you!!! #diversity #clinicaltrials #RepresentationMatters @emilebachamd @SantosGallegoMD

3

7

38

2

6

30

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

A great FIRST step to increase the pool of heart transplants! @j_alvarezgarcia @m_rivaslasarte @yulnunezvill @acorderofort @dranulala @AndrewJSauer @VerwerftJan @FH_Verbrugge @hvanspall @ShelleyZieroth

3

8

31

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

What are the effects of the SGLT2 inhibitor empagliflozin on iron metabolism in HFrEF? Do not miss this presentation! @RequenaIbanez @ChristophMaack @CEAngermann @dranulala @Jcontreras75 @HanCardiomd @ValleAlfonso

Mount Sinai Fuster Heart Hospital

@MountSinaiHeart

3 years

Be sure to tune in tomorrow to learn about @SantosGallegoMD 's research on the effects of #empaglifozin on iron #metabolism , featured at #AHA21 . Register at: @AHAMeetings @American_Heart

0

4

24

2

9

30

Carlos G Santos-Gallego, MD

@SantosGallegoMD

11 months

Congrats to the great @DLBHATTMD for his induction yesterday into the New York Academy of Medicine @NYAMNYC !! And for being named two days ago the Valentin Fuster endowed Chair & Professor!! Very well deserved! You are on a roll!

Dr. Deepak L. Bhatt

@DLBHATTMD

11 months

Wonderful evening at the @NYAMNYC fellowship induction ceremony. Keynote speaker Dr. @KBibbinsDomingo , the editor-in-chief of @JAMA_current , made it special. @JAMANetwork @MountSinaiHeart @BethOliverVP @DrDavidReich @JAMACardio @IcahnMountSinai @MountSinaiNYC

3

74

2

0

31

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

@AndrewJSauer @adrianbye As a fellow, I learnt more from “Sues” than from many doctors

0

1

29

Carlos G Santos-Gallego, MD

@SantosGallegoMD

3 years

Good morning! Welcome to another wonderful day lf #CVCT2021 Let’s discuss HFpEF beyond LV stiffness

1

11

30

Carlos G Santos-Gallego, MD

@SantosGallegoMD

1 year

Happy birthday to an amazing scientist, cardiologist and person! @Hinaheartdoc @bingyanw @sanginair @RequenaIbanez @juanbadimon @DLBHATTMD @DrDavidReich @rahatheart1 @AnastasiaSMihai @aayshacader @ErinMichos

6

1

30

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

What do nephrologist think of this? As @RyanTedfordMD said, “I cannot hear you” @ChristosArgyrop @kidney_boy @NephroGuy @nephondemand @NephroP @edgarvlermamd @NephJC @kirkcampbell @aishaikh @Nephro_Sparks @askrenal @VelezNephHepato @beaff26 @captainchloride @hswapnil @HanCardiomd

Eiran Gorodeski, MD, MPH

@EiranGorodeski

2 years

Lasix 500mg tablets available in Kuwait. #Congestion is the enemy in heart failure. Do not be afraid!!

145

232

2K

17

5

27

Carlos G Santos-Gallego, MD

@SantosGallegoMD

2 years

A great pleasure to receive an invitation to lecture in this event of Cardiology Critic Care in Guayaquil, Ecuador! And with old friends @drdargaray @lucreciamburgos @paomorejon (🥐commando, @hvanspall ) Congrats @paomorejon @MoniGilbertO for organizing this ambitious event!

Paola Morejón Barragán

@paomorejon

2 years

🗓 I Jornadas Internacionales de Cardiología Crítica🫀🇪🇸🇺🇸🇨🇴🇦🇷🇲🇽 Inscripciones: Envío de trabajos: Becas virtuales para colegas en el extranjero‼️ Los esperamos‼️ @MoniGilbertO #ClinicaGuayaquil #CardioEd #CardioTwitter

5

21

54

5

3

29

Carlos G Santos-Gallego, MD

@SantosGallegoMD

4 years

Our EMPATROPISM clinical trial has been presented at AHA as Featured Clinical Trial, with simultaneous publication at @JACCjournals ! What an honor! A tweetorial 👇

Alfonso Valle

@ValleAlfonso

4 years

#EMPA -TROPISM trial via @SantosGallegoMD @MountSinaiNYC 👥84 HFrEF ⚠️Non-diabetic ⏱6m 💊43%ARNI 88%BB 42% ACE/ARB #Empagliflozin ⤵️ 🔽LVEDVI -25.1ml 🔽LVESVI -26.6ml 🔽LVmass -17.8g 🔼EF 6% 🔼VO2max +1.1ml/min/Kg 🔼OUES +111 🔼6mWalkTest +81m 🔼KCCQ +21

2

20

42

1

5

26